MiNK Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for MiNK Therapeutics, Inc. (INKT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-10.78-22.46-27.99-30.21-16.24
Depreciation & Amortization0.220.200.120.080.06
Stock Based Compensation1.813.863.031.740.09
Change in Working Capital0.462.908.773.741.48
Change in Accounts Payable-1.18-1.922.66-0.150.61
Change in Other Working Capital1.644.81-2.793.891.06
Other Operating Activities-1.07-0.27-2.7913.936.28
Net Cash from Operating Activities-9.56-15.76-18.87-12.83-8.34
Investing Activities
Capital Expenditures0.00-0.07-0.250.25-0.10
Net Cash from Investing Activities0.00-0.07-0.25-0.25-0.10
Financing Activities
Debt Repayment5.000.000.000.000.00
Common Stock Issued5.820.070.0039.800.00
Common Stock Repurchased0.00-0.48-0.160.000.00
Other Financing Activities0.020.00-0.169.460.00
Net Cash from Financing Activities10.82-0.41-0.1649.2611.11
Summary
Effect of Forex Changes on Cash-0.05-0.030.020.020.00
Net Change in Cash1.21-16.27-19.2736.202.39
Cash at Beginning of Period3.3719.6438.892.690.00
Cash at End of Period4.58-22.2519.6438.890.00
Free Cash Flow-9.56-15.84-19.12-13.08-8.43
Supplemental Disclosures
Interest Paid0.010.030.010.000.00